Dermata Therapeutics, Inc. (DRMA) Key Statistics & Metrics

Dermata Therapeutics, Inc. (DRMA) has an ST Score of 45.0 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate DRMA a Buy, with a price target of $6.00 (+412.8% vs the current price). Our ST Score grades it C+ (45.0/100). The ST Score is a data-driven signal, not a recommendation.

Valuation C+, Profitability F, Financial Strength C+, Momentum C-, Growth A+, Forecast A.

Dermata Therapeutics, Inc. (DRMA) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Dermata Therapeutics, Inc. (DRMA) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Dermata Therapeutics, Inc. (DRMA) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Dermata Therapeutics, Inc. (DRMA) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Dermata Therapeutics, Inc. (DRMA) is $6.00 from 1 analysts, which is +412.8% versus the recent price of $1.17.

Dermata Therapeutics, Inc. (DRMA) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.